

Human Microbiome-based Drugs and Diagnostics: Global Markets

Market Research Report | 2025-05-23 | 116 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$4650.00
- 2-5 Users License \$5580.00
- Site License \$6696.00
- Enterprise License \$8035.00

Report description:

Description

Report Scope

The report analyzes the global market for human microbiome-based drugs and diagnostics and market trends. It includes global revenues for the base year 2024, estimated data for 2025 and the compound annual growth rates (CAGRs) for forecast period of 2025 to 2030. The market is segmented by type, application, end user and region. The microbiome-based drug segment is further segmented by route of administration: oral or rectal. Microbiome-based diagnostics are segmented based on product type into instruments, and reagents and kits. End-user segments include hospitals and clinics, pharmaceutical companies and research institutes. Applications include metabolic, gastrointestinal (GI) and infectious diseases, cancer and others. The regions covered include North America, Europe, Asia-Pacific, South America and the Middle East and Africa (MEA). The report discusses emerging technologies and analyzes the competitive landscape, providing the ranking/market shares of leading companies in the market. It also includes a chapter on environmental, social and corporate governance (ESG) developments.

Human microbiome-based products that are intended for wellness or as dietary supplements are outside the scope of the report, as are nonstandardized fecal microbiota transplantation (FMT) procedures. Microbiome-based diagnostics include only products that claim to detect or screen for any disease or condition.

Report Includes

- 55 data tables and 51 additional tables
- Analyses of the trends in global markets for human microbiome-based drugs and diagnostics, with revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
- Estimates of the size and revenue prospects for the global market, along with a market share analysis by type, drug route of administration, diagnostics product type, application, end user, and region
- Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations, and the impacts of macroeconomic variables
- Review of the prevalence of infectious diseases, metabolic disorders and chronic ailments

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- An assessment of current products, clinical trials and identification of new potential markets for novel products and assay development
- Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes
- An analysis of the key patent grants and recently published patents
- Analysis of the industry structure and value chain, and the competitive landscape, including companies' market shares, strategic alliances, M&A activity, venture fundings and investment outlook
- Profiles of the leading companies, including Ferring Pharmaceuticals, Nestlé Health Science, BiomeBank, Genetic Analysis AS, and Vedanta Biosciences Inc.

Executive Summary

Summary:

The global market for human microbiome-based drugs and diagnostics is expected to grow from \$393.4 million in 2025 to reach \$1.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 25.6% from 2025 through 2030.

Human microbiome-based drugs and diagnostics are novel approaches to tackling difficult-to-treat diseases. The growing understanding of the human microbiome can be leveraged to fill the gaps in conventional treatment options. A wide range of scientific studies have demonstrated the role of microbiomes in the pathogenesis of various diseases. The microbiome field is also witnessing an increased level of investments from the private and public sectors. Future opportunities in the market lie in exploring microbiomes in other body parts, such as lungs, and developing microbiome-based drugs as combination therapies. Leading companies in the market for human microbiome-based drugs and diagnostics include Ferring, Nestlé Health Science (Seres Therapeutics), BiomeBank, Genetic Analysis AS and Vedanta Biosciences.

Table of Contents:

- Table of Contents
- Chapter 1 Executive Summary
 - Market Outlook
 - Scope of Report
 - Market Summary
 - Market Dynamics
 - Emerging Technologies
 - Analysis by Segment
 - Regional Analysis
 - Conclusion
- Chapter 2 Market Overview
 - Overview and Market Definition
 - Different Microbiomes in Humans
 - Microbiome, Human Health and Disease
 - Technologies Aiding Microbiome Research
 - Culturing and Cultivation
 - Strategies for the Development of Microbiome Therapeutics
 - Additive Microbiome Therapy
 - Modulatory Microbiome Therapy
 - Analysis of Macroeconomic Factors
 - Geopolitical Factors

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Inflation and Currency Exchange Fluctuations
Porter's Five Forces Analysis
Chapter 3 Market Dynamics
Takeaways
Market Drivers
Growing Evidence of Microbiome-disease Correlation
Microbiome-based Diagnostics for Disease Prevention and Monitoring
Market Restraints
Challenges in Clinical Trial Design
Lack of Established Regulatory Frameworks
High Costs of Microbiome Therapeutics
Market Opportunities
Direct-to-Consumer Microbiome Testing
Drugs and Diagnostics for Lung and Skin Microbiomes
Chapter 4 Regulatory Landscape
Regulatory Aspects
North America
Europe
Asia-Pacific
Chapter 5 Emerging Technologies
Takeaways
Emerging Technologies
Microbial Ecosystem Therapeutics
Metatranscriptome Sequencing
Genetically Modified Microbiome Therapeutics
Combination and Adjuvant Therapies with Microbiome-based Drugs
Novel Preclinical Models
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Market Analysis by Type
Microbiome-based Drugs
Market Analysis by Application
Infectious Diseases
GI Disorders
Metabolic Disorders
Cancer
Other Diseases
Market Analysis by End User
Hospitals and Clinics
Research Institutions
Pharmaceutical Companies
Geographic Breakdown
Market Analysis by Region
North America
Europe
Asia-Pacific
South America

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Middle East and Africa
Chapter 7 Competitive Intelligence
Takeaways
Company Share Analysis
Competitive Analysis
Venture Funding and Investment Landscape
Recent Developments
Chapter 8 Sustainability in the Human Microbiome-based Drugs and Diagnostics Industry: An ESG Perspective
Introduction to ESG
ESG Risk Ratings
Concluding Remarks
Chapter 9 Appendix
Methodology
Sources
Abbreviations
Company Profiles
BIOMEBANK
ENTERBIOTIX LTD.
ENTEROME
FERRING
GENETIC ANALYSIS
ILLUMINA INC.
MICROBIOME INSIGHTS
MICROBIOTICA
NESTLE HEALTH SCIENCE
OXFORD NANOPORE TECHNOLOGIES PLC
PACBIO
SFA THERAPEUTICS INC.
THERMO FISHER SCIENTIFIC INC.
VEDANTA BIOSCIENCES INC.
Emerging Start-ups/Market Disruptors

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Human Microbiome-based Drugs and Diagnostics: Global Markets

Market Research Report | 2025-05-23 | 116 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4650.00
	2-5 Users License	\$5580.00
	Site License	\$6696.00
	Enterprise License	\$8035.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-09"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

